Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Voluntarily sign and date an informed consent agreement
Have participated in and completed the double-blind study EN3835-201
Be willing to apply sunscreen to any treated quadrant before each exposure to sun
Voluntarily sign and date an informed consent agreement
Have participated in and completed the double-blind study EN3835-201
Be willing to apply sunscreen to any treated quadrant before each exposure to sun
Have at least 1 quadrant with: a score of 3 or 4 (moderate or severe) as reported on the PCSS (Photonumeric Cellulite Severity Scale) by the subject or investigator, and a Hexsel CSS (Cellulite Severity Scale) score no greater than 13
Be judged to be in good health
Have a negative urine pregnancy test at screening and be using an effective contraception method, be surgically sterile, or post-menopausal
You may not be if
None
Has used, or intends to use during the course of the study, other treatment of EFP on the legs or buttocks
Is presently nursing a baby or providing breast milk for a baby
Intends to become pregnant during the study
Currently receiving, has received within 7 days before injection of study drug, or plans to receive an anticoagulant or antiplatelet medication
History of stroke or bleeding
Clareo Health | EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
